Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal)

NCT00353080 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00353080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00353080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2002
Completion date
April 30, 2005
Enrollment
171 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, postmenopausal